|Articles|June 9, 2004
Santen Pharmaceuticals ends phaco device development
Phacor Inc., the California-based wholly owned subsidiary of Santen Pharmaceuticals Co. Ltd., ceased operations after 6 years of phacoemulsification system development.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
From bench to bedside: Evolving realities of gene therapy for inherited retinal diseases
2
8 things to know about aflibercept 8 mg for retinal vascular disease
3
Topical liposomal ozonated oil may be a useful treatment in neurotrophic keratopathy
4
Seeing the difference: Multimodal imaging for AMD and GA
5



































